Cytokinetics to Announce Fourth Quarter Results on February 16, 2017
February 03 2017 - 4:00PM
Cytokinetics, Inc. (Nasdaq:CYTK) today announced that it is
scheduled to report fourth quarter results on Thursday, February
16, 2017 at 4:00 PM Eastern Time. Following the announcement,
Cytokinetics’ senior management will host a conference call at 4:30
PM Eastern Time to discuss operational and financial results and
the company’s outlook for the future.
The conference call will be simultaneously
webcast and can be accessed from the homepage and in the Investors
& Media section of Cytokinetics’ website at
www.cytokinetics.com. The live audio of the conference call can
also be accessed by telephone by dialing either (866) 999-CYTK
(2985) (United States and Canada) or (706) 679-3078 (international)
and typing in the passcode 46421080.
An archived replay of the webcast will be
available via Cytokinetics' website until February 23, 2017. The
replay will also be available via telephone by dialing (855)
859-2056 (United States and Canada) or (404) 537-3406
(international) and typing in the passcode 46421080 from February
16, 2017 at 5:30 PM Eastern Time until February 23, 2017.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical
company focused on discovering, developing and commercializing
first-in-class muscle activators as potential treatments for
debilitating diseases in which muscle performance is compromised
and/or declining. As a leader in muscle biology and the mechanics
of muscle performance, the company is developing small molecule
drug candidates specifically engineered to increase muscle function
and contractility. Cytokinetics’ lead drug candidate
is tirasemtiv, a fast skeletal muscle troponin
activator. Tirasemtiv is the subject of VITALITY-ALS, an
international Phase 3 clinical trial in patients with
ALS. Tirasemtiv has been granted orphan drug designation
and fast track status by the U.S. Food and Drug
Administration and orphan medicinal product designation by the
European Medicines Agency. Cytokinetics is preparing for the
potential commercialization of tirasemtiv in North America and
Europe and has granted an option to Astellas Pharma
Inc. for development and commercialization in other countries.
Cytokinetics is collaborating with Astellas to develop CK-2127107,
a next-generation fast skeletal muscle activator. CK-2127107 is the
subject of two ongoing Phase 2 clinical trials enrolling patients
with spinal muscular atrophy and chronic obstructive pulmonary
disease. Cytokinetics is collaborating with Amgen Inc. to
develop omecamtiv mecarbil, a novel cardiac muscle
activator. Omecamtiv mecarbil is the subject of
GALACTIC-HF, an international Phase 3 clinical trial in patients
with heart failure. Amgen holds an exclusive worldwide license to
develop and commercialize omecamtiv mecarbil with a
sublicense held by Servier for commercialization in Europe and
certain other countries; Astellas holds an exclusive worldwide
license to develop and commercialize CK-2127107. Licenses held
by Amgen and Astellas are subject to Cytokinetics' specified
co-development and co-commercialization participation rights. For
additional information about Cytokinetics,
visit http://www.cytokinetics.com/.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the “Act”). Cytokinetics disclaims any intent or
obligation to update these forward-looking statements, and claims
the protection of the Act’s safe harbor for forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to planned presentations, and the
properties and potential benefits of Cytokinetics’ drug candidates
and potential drug candidates. Such statements are based on
management’s current expectations, but actual results may differ
materially due to various risks and uncertainties, including, but
not limited to, potential difficulties or delays in the
development, testing, regulatory approval and production of
Cytokinetics' drug candidates and potential drug candidates that
could slow or prevent clinical development or product approval,
including risks that current and past results of clinical trials or
preclinical studies may not be indicative of future clinical trials
results and that Cytokinetics' drug candidates and potential drug
candidates may have unexpected adverse side effects or inadequate
therapeutic efficacy. For further information regarding these and
other risks related to Cytokinetics’ business, investors should
consult Cytokinetics’ filings with the Securities and Exchange
Commission.
Contact:
Cytokinetics
Diane Weiser
Vice President, Corporate Communications, Investor Relations
(650) 624-3060
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Sep 2023 to Sep 2024